Impaired Eyeblink Conditioning and Decreased Hippocampal Volume in PDAPP V717F Mice

We examined heterozygous transgenic (Tg) mice that overexpress V717F amyloid precursor protein (APP) for delay eyeblink conditioning (EBC) and hippocampal volume with magnetic resonance imaging (MRI). Platelet-derived APP mice were significantly impaired on EBC relative to wild type (WT) litter-mate controls. T2-weighted spin echo images (62.5 x 125 x 500 microm) of the same mice were acquired under anesthesia using a 9.4T magnet. Tg mice had hippocampal to brain volume ratios that were significantly smaller than WT controls (31% smaller in the rostral dorsal hippocampus, 13-22% smaller among equal dorsal-ventral thirds of a caudal section). These results indicate that overexpression of APP or beta amyloid profoundly affects learning and memory and hippocampal volume. The results also indicate that eyeblink conditioning and quantitative MRI in mice may be useful assays to follow the progression of disease-related changes, and to test the effectiveness of potential therapeutics against Alzheimer's disease.

[1]  D. Woodruff-Pak,et al.  Eyeblink conditioning discriminates Alzheimer's patients from non-demented aged. , 1990, Neuroreport.

[2]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[3]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[4]  Bin Zhang,et al.  In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. , 2000 .

[5]  F. Morrell,et al.  Alzheimer’s Disease: In Vivo Detection of Differential Vulnerability of Brain Regions , 1997, Neurobiology of Aging.

[6]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[7]  J F Disterhoft,et al.  Trace eyeblink conditioning in the freely moving rat: optimizing the conditioning parameters. , 1999, Behavioral neuroscience.

[8]  R. F. Thompson,et al.  Neural mechanisms of classical conditioning in mammals. , 1990, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[9]  L. Mucke,et al.  Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β-Amyloid Precursor Protein and Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[10]  P. Solomon,et al.  Altered activity in the hippocampus is more detrimental to classical conditioning than removing the structure. , 1983, Science.

[11]  R. Motter,et al.  Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[12]  L. Mucke,et al.  Levels and Alternative Splicing of Amyloid β Protein Precursor (APP) Transcripts in Brains of APP Transgenic Mice and Humans with Alzheimer's Disease (*) , 1995, The Journal of Biological Chemistry.

[13]  M. Moser,et al.  Functional differentiation in the hippocampus , 1998, Hippocampus.

[14]  Diana S. Woodruff-Pak,et al.  Eyeblink classical conditioning in Alzheimer's disease and cerebrovascular dementia , 1996, Neurobiology of Aging.

[15]  Richard F. Thompson,et al.  Delayed acquisition of eyeblink conditioning in aged F1 hybrid (Fischer-344 × brown Norway) rats , 1992, Neurobiology of Aging.

[16]  P. Solomon,et al.  Classical conditioning in patients with Alzheimer's disease: a multiday study. , 1995, Psychology and aging.

[17]  Craig Weiss,et al.  Hippocampal lesions prevent trace eyeblink conditioning in the freely moving rat , 1999, Behavioural Brain Research.

[18]  George A. Carlson,et al.  The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[19]  Guiquan Chen,et al.  A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease , 2000, Nature.

[20]  R. Nicoll,et al.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B T Hyman,et al.  Growth Arrest of Individual Senile Plaques in a Model of Alzheimer's Disease Observed by In Vivo Multiphoton Microscopy , 2001, The Journal of Neuroscience.

[22]  S. Paul,et al.  Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Solomon,et al.  Disruption of human eyeblink conditioning after central cholinergic blockade with scopolamine. , 1993, Behavioral neuroscience.

[24]  S. Bao,et al.  Bilateral lesions of the interpositus nucleus completely prevent eyeblink conditioning in Purkinje cell-degeneration mutant mice. , 1999, Behavioral neuroscience.

[25]  S. Paul,et al.  Neuroanatomical Abnormalities in Behaviorally Characterized APPV717F Transgenic Mice , 2000, Neurobiology of Disease.

[26]  I. Gormezano,et al.  Effects of scopolamine and methylscopolamine on classical conditioning of the rabbit nictitating membrane response. , 1983, The Journal of pharmacology and experimental therapeutics.

[27]  D. Borchelt,et al.  Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins , 1995, Neuron.

[28]  F. Gonzalez-Lima,et al.  Reduced corpus callosum, fornix and hippocampus in PDAPP transgenic mouse model of Alzheimer's disease , 2001, Neuroreport.

[29]  A Routtenberg,et al.  Measuring memory in a mouse model of Alzheimer's disease. , 1997, Science.

[30]  Richard F. Thompson,et al.  Hippocampus and trace conditioning of the rabbit's classically conditioned nictitating membrane response. , 1986, Behavioral neuroscience.

[31]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[32]  T. Bliss,et al.  Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice , 1999, Nature Neuroscience.

[33]  H. Meziane,et al.  Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. , 1999, Behavioral neuroscience.

[34]  G. Fein,et al.  Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease , 1997, Neurology.

[35]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[36]  JOHN W. Moore,et al.  Central cholinergic blockade by scopolamine and habituation, classical conditioning, and latent inhibition of the rabbit’s nictitating membrane response , 1976 .

[37]  Chantal Mathis,et al.  Early regional cerebral glucose hypometabolism in transgenic mice overexpressing the V717F β-amyloid precursor protein , 1999, Neuroscience Letters.